Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia [6]

Leukemia and Lymphoma

Volumn 48, Issue 7, 2007, Pages 1426-1428

  Ali, Ridvan ^a   Beksac, Meral ^b   Ozkalemkas, Fahir ^a   Ozkocaman, Vildan ^a   Ozkan, Atilla ^a   Ozcelik, Tulay ^a   Tunali, Ahmet ^a  

^a ULUDAG UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; BLOOD CLOTTING FACTOR 5 LEIDEN; BORTEZOMIB; CALCIUM; CD38 ANTIGEN; CD79A ANTIGEN; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; IMMUNOGLOBULIN KAPPA CHAIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ADULT; ANOREXIA; BLOOD SMEAR; BLOOD TOXICITY; BOLUS INJECTION; BONE MARROW BIOPSY; CASE REPORT; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG TREATMENT FAILURE; FATIGUE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; INFORMED CONSENT; LETTER; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PLASMA CELL; PLASMA CELL LEUKEMIA; PNEUMONIA; PRIORITY JOURNAL; PURPURA; RECURRENT CANCER; SENSORY NEUROPATHY; SINGLE DRUG DOSE; THROMBOCYTE COUNT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; HUMANS; LEUKEMIA, PLASMACYTIC; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS, SECOND PRIMARY; PYRAZINES; TREATMENT OUTCOME;

EID: 34447545662     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701370597     Document Type: Letter

References (15)

1. Finnegan, D PJ, Kettle, P., Drake, M., Matthews, C., Alexander, H. D. and Popat, R. (2006) Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma, 47, pp. 1670-1673.
2. Richardson, P. G., Mitsiades, C. S., Hideshima, T. and Anderson, K. C. (2005) Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Haematol, 18, pp. 619-634.
3. Catley, L., Tai, Y. T., Chauhan, D. and Anderson, K. C. (2005) Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resist Updat, 8, pp. 205-218.
4. Barlogie, B., Smith, L. and Alexanian, R. (1984) Effective treatment of advanced myeloma refractory to alkylating agents. N Engl J Med, 310, pp. 1353-1356.
5. Cavo, M. (2006) Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia, 20, pp. 1341-1352.
6. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V. J., Elliott, P. J. and Adams, J. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res, 61, pp. 3071-3076.
7. Mitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V., Tai, Y. T. and Chauhan, D. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood, 101, pp. 2377-2380.
8. Oakervee, H. E., Popat, R., Curry, N., Smith, P., Morris, C. and Drake, M. (2005) PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol, 129, pp. 755-762.
9. Jimenez-Zepeda, V. H. and Dominguez, V. J. (2006) Plasma cell leukemia: a rare condition. Ann Hematol, 85, pp. 263-267.
10. Gertz, M. A. (2007) Managing plasma cell leukemia. Leuk Lymphoma, 48, pp. 5-6.
11. Petrucci, M. T., Martini, V., Levi, A., Gallucci, C., Palumbo, G. and Bianco, P Del (2007) Thalidomide does not modify the prognosis of plasma cell leukemia patients: Experience of a single center. Leuk Lymphoma, 48, pp. 180-182.
12. Esparis-Ogando, A., Alegre, A., Aguado, B., Mateo, G., Gutierrez, N. and Blade, J. (2005) Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer, 114, pp. 665-667.
13. Jaskiewicz, A. D., Herrington, J. D. and Wong, L. (2005) Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy, 25, pp. 1820-1825.
14. Grassinger, J., Sudhoff, T., Andreesen, R. and Hennemann, B. (2006) Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol, 85, pp. 132-133.
15. Ataergin, S., Arpaci, F., Kaya, A., Cetin, T. and Gunhan, O. (2006) VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia. Am J Hematol, 81, pp. 987-988.